DCAT Value Chain Insights’ Production to Prescription

DCAT

DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

  1. 5 DAYS AGO

    What’s Trending: ADCs: Pipelines, Products, & CDMO Growth

    Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights.    Support the show

    20 min

  2. 16 OCT

    Drug Launches & Approvals in 2025: The Blockbuster Contenders

    Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights.   Support the show

    17 min

  3. 4 SEPT

    CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

    What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and in key geographic markets: Europe, Canada, India and China? How will major segments, innovator drug and generics/biosimilar be affected?   Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Contract Services Practice. Support the show

    26 min

  4. 5 JUN

    Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?

    Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important barometer of the financial health of the sectors, has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn? Featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY) Support the show

    36 min

  5. 8 MAY

    Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?

    As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains.   Support the show

    17 min

  6. 3 APR

    Biomanufacturing: How are Industry Capacity & Supply Chains Trending?

    What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains.  Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates Support the show

    39 min

  7. 6 FEB

    Parenteral Drug Mfg—CDMO Outlook: a Capacity Crunch of Easing?

    How are supply and demand shaping up for sterile manufacturing and aseptic fill–finish in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such as GLP-1 agonist impact market fundamentals.     Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals, vaccines, and leads L.E.K.’s Pharmaceutical Contract Services practice.  Support the show

    28 min

  8. 30/12/2024

    Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead

    What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI.   Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP Support the show

    25 min
See All (52)

About

DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

Information

You Might Also Like